Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.

about

Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.

Item

http://www.wikidata.org/entity/Q47656490

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.

@en

Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.

@nl

type

Item

label

Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.

@en

Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.

@nl

prefLabel

Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.

@en

Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.

@nl

P1476

Cost Effectiveness of Imatinib ...... nic Myeloid Leukemia in China.

@en

P2093

Bin Zheng

http://www.w3.org/2001/XMLSchema#string

Feng-Mei Zhan

http://www.w3.org/2001/XMLSchema#string

Hong-Fu Cai

http://www.w3.org/2001/XMLSchema#string

Jing Yang

http://www.w3.org/2001/XMLSchema#string

Li-Zhu Weng

http://www.w3.org/2001/XMLSchema#string

Mao-Bai Liu

http://www.w3.org/2001/XMLSchema#string

Na Li

http://www.w3.org/2001/XMLSchema#string

Xiao-Feng Luo

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.

An introduction to Markov modelling for economic evaluation.

Development of WHO guidelines on generalized cost-effectiveness analysis.

Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.

Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.

Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

P304

79-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40261-017-0587-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29027641

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia